Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat CLL (US)

March 20, 2008
Revlimid in non-myeloma malignancies? A review article? It's time is coming!
By a GLG Expert Contributor
Analysis of: Lenalidomide for the Treatment of B-Cell Malignancies (jco.ascopubs.org)
Revlimid has significant activity in non Hodgkin's lymphomas (NHL)as well as chronic lymphatic leukemia (CLL) although why is somewhat unclear.
March 19, 2008
Avastin (Genentech) a double edged sword?
By a GLG Expert Contributor
Analysis of: Doctors See How Cancer Drug Can Damage Kidneys (www.washingtonpost.com)
Avastin, an antiangiogenic agent used in cancer and other disorders, may have more side effects than originally recognized including proteinuria as well as kidney damage.
March 17, 2008
Genzyme's Cerezyme: When is enough enough
By a GLG Expert Contributor
Analysis of: Cutting Dosage of Costly Drug Spurs a Debate (www.nytimes.com)
Pharma recommends more drug than may actually be needed. This does not apply just to Cerezyme, but the Epo products (Amgen & J&J), Avastin (Genentech.)
March 17, 2008
Fraud: Inevitable no matter who is in charge
By a GLG Expert Contributor
Analysis of: 5 Guilty of Fraud in Health Care Finance (www.nytimes.com)
Prison terms to be handed out for fraud by a health care financing firm. Go figure?
March 14, 2008
The FDA givith (Amgen's Nplate) and takith away (Amgen's Aranesp)
By a GLG Expert Contributor
Analysis of: Platelet Treatment Wins FDA Panel's Support (online.wsj.com)
This is an agent, approved for use with restrictions, in ITP.
March 14, 2008
FDA & Epo: Not as bad as expected!
By a GLG Expert Contributor
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits (online.wsj.com)
Epo products (Aranesp, Procrit, Epogen) from Amgen and J & J will be restricted to some degree with control of hemoglobin levels, NO use in curable malignancies ..." the panel voted 11 to 2 in recommending that the drugs not be used in cancer patients who are likely to be cured from their...
March 14, 2008
Nplate: An effective parenteral therapy for refractory chronic ITP
By a GLG Expert Contributor
Analysis of: Platelet Treatment Wins FDA Panel's Support (online.wsj.com)
FDA panel recommned approval of Amgen's Nplate for patients with refractory/recurrent chronic ITP who have failed other therapies like steroids, immunoglobulins, Rituximab and spleenectomy. The safety/efficacy profile was favorable for this relatively narrow indication, although long term safet issues...
March 14, 2008
FDA panel recommendations means less sales of ESA'a and negative implications for Amgen
By a GLG Expert Contributor
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits (online.wsj.com)
An FDA panel recommended NOT to use ESA's for treatment of chemotherapy induced anemia in Breast cancer patients and head and neck acncer patients, a significant number of cancer patients. It also voted overwhelmingly to limit ESA's for non-curable cancer patients in the setting of palliative care....
March 11, 2008
A third world country balking at the cost of high priced cancer drugs their citizens can't afford? Go figure....
By a GLG Expert Contributor
Analysis of: Thai Ministry to Recommend Ignoring Patents on Cancer Drugs (online.wsj.com)
Manufacturers include Roche Holding AG and Novartis AG of Switzerland and Sanofi-Aventis. Generic versions of the antineoplastic agents will be made available and the patents obviously ignored.
March 11, 2008
Avastin: Not for every one with breast cancer, but benefit is real for selected patients.
By a GLG Expert Contributor
Analysis of: The High Cost of a Cancer Drug (www.nytimes.com)
FDA's approval of Genentech's Avastin is backed both by efficacy data and aggressive political activism. Extension of PFS by almost 6 months and shrinking large tumors, thus improving quality of life, are tangible and real beneficial effects. Avastin was already being prescribed off-label. The approval...

Previous Page : 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next161 to 170 of 701

Analytics


Generated at 2009-01-07T13:00:17.563